Risk factors for the development of interstitial lung disease following severe COVID ... Short-Form 6-Dimension and King's Sarcoidosis Questionnaire in people with sarcoidosis associated fatigue.

Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

Cardiac sarcoidosis and cystic fibrosis (CF) are both rare conditions and their co-existence has not previously been noted in ...

Sarcoidosis affects the lungs, skin and lymph nodes most of the time if you have the condition. These are the symptoms for each organ. The lungs are affected in about nine out of ten of people ...

Simon Osborne had to stop working after sarcoidosis badly affected his lung capacity A former plasterer with a rare lung condition will trial a new kind of medicine that could help treat it.

Innovative research on Cell-free DNA (cfDNA) and other novel biomarkers for improved cardiac sarcoidosis and heart health ...

Sarcoidosis is an inflammatory disease characterized by the formation of granulomas in one or more organs of the body. When left unchecked, chronic inflammation caused by granulomas can lead to ...

aTyr Pharma has a pivotal year ahead with key readouts for Efzofitimod in pulmonary sarcoidosis and SSC-ILD, potentially opening a huge market. Efzofitimod aims to modulate inflammation without ...

Enrollment completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data expected in the third quarter of 2025. Publication in European Respiratory Journal demonstrated ...